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ABSTRACT 
Objectives: The present study was undertaken to determine the prevalence of multi drug resistant (MDR) and multiple β-lactamase producing 
Pseudomonas aeruginosa isolates in lower respiratory tract infection (LRTI) patients at a tertiary care hospital in India.  
Methods: A total of 80 consecutive, non-duplicate isolates of P. aeruginosa were studied for the presence of class A or B β-lactamase. Antibiotic 
susceptibility tests and PCR amplification of genes encoding class A (PER-1 and CTX-M 1, 2, 9) and class B β-lactamases (blaVIM-2, blaIMP-1 and 
blaSIM-1) were performed.  
Results: Out of 80 P. aeruginosa isolates, 65% (52/80) of the isolates were MDR with 34 being Metallo-β-lactamase (MBL) producers, 23 were 
extended spectrum β-lactamase (ESBL) producers and 21 were positive for AmpC production. The cross-class resistance rates to other antibiotics 
was significantly higher in class A and B β-lactamase producers than in non-producers (P<0.05 for fluoroquinolone, aztreonam, ceftazidime and 
meropenem). Combined disk test (CDT) for MBL highest sensitivity and specificity compared to PCR. Combined disk method (CDM) for ESBL co-
related well with PCR (sensitivity and specificity).  
Conclusion: This study reports the validation of a simple and accurate MBL and ESBL detection method which can be easily integrated into the 
daily routine of a clinical laboratory. 
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INTRODUCTION 
Pseudomonas aeruginosa is considered as the most commonly 
isolated Gram-negative organism in the blood stream, wound 
infections, pneumonia, abdominal and urogenital sepsis. It also 
infects immune compromised patients, these poses a serious health 
issue [1].  
P. aeruginosa shows high antibiotic resistance which can be due to 
several factors working synergistically i.e., over expression of efflux 
pumps as well as chromosomal or plasmid encoded beta lactamases.  
Metallo-beta-lactamases (MBLs) are called carbapenemases which 
includes the VIM and IMP and their variants such as SPM-1, GIM-1, 
NDM-1, AIM-1 and SIM-1 enzymes.  
The VIM and IMP enzymes are by far the most common MBLs found 
in carbapenem-resistant bacteria, including carbapenem-resistant P. 
aeruginosa [2]. 
Extended-spectrum ß-lactamases (ESBLs) are encoded by plasmid 
genes TEM, SHV and CTX-M-genes, which show resistance to 
penicillins, 3rd generation cephalosporins and also to later 
generation cephalosporins such as Cefepime, cefotaxime and 
ceftazidime [3].  
Thus, the present study was conducted with an objective to know 
the anti biogram and to detect the presence of ESBL and MBL 
producing P. aeruginosa, so as to help in formulating an effective 
antibiotic and hospital infection strategy to prevent the spread of 
these strains. 
MATERIALS AND METHODS  
Study site and subjects 
LRTI patients attending outpatients ward or admitted in the ward in 
department Pulmonary medicine at a tertiary care hospital in 
Lucknow, India during September 2010 to August 2012 were 
enrolled. The inclusion criteria for patient enrollment was ≥ 18-
years of age with symptoms suggestive of LRTI (i.e., two or more of 
the following symptoms: cough, sputum production, shortness of 
breath, wheeze, fever during this illness, chest pain) and who gave 
written consent for participation. 
Sample processing 
Samples obtained were cultured on MacConkey and Pseudomonas 
isolation agar plates (Hi-media) and incubated at 37 °C for 16-18 
hrs. Identification of P. aeruginosa isolates was done by standard 
biochemical procedure [4]. 
Antibiotic susceptibility testing 
Susceptibility of the isolates was tested by Kirby Bauer disk 
diffusion method as per Clinical and Laboratory Standards Institute 
(CLSI) 2010guidelines [5].  
P. aeruginosa ATCC 27853 was used as quality control. Antimicrobial 
susceptibility profiles were compared for class A and B β-lactamase 
producers and non-producers. Strains resistant to all of the agents in 
2 or more of the following antimicrobial categories were defined as 
multiresistant: β-lactam antibiotics, including imipenem, amino-
glycosides, and the fluoroquinolones ciprofloxacin [6]. 
MIC of meropenem and ceftazidime by agar dilution method  
Minimum inhibitory concentration of meropenem and ceftazidime 
resistant strains was determined by the agar dilution method [5]. 
Dilutions of meropenem and ceftazidime ranging from 2 µg/ml 
to128 µg/ml were prepared in doubles. MIC of ≥ 16 µg/ml was 
interpreted as resistant [5]. Both antibiotic powders were obtained 
from HIMEDIA, Mumbai, India. 
Phenotypic detection of MBL, ESBL and Amp-C-β-lactamase  
Detection of the ESBLs 
All the isolates of P. aeruginosa, which showed resistance to 
ceftazidime were evaluated for ESBL production by using 
combination disk method (CDM) [7] and double-disk approximation 
test (DDAT) [8]. 
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Detection of the Ampc β-lactamases 
In the initial screening test, a disc of cefoxitin (FOX-30 μg) was 
placed on a Mueller Hinton agar plate already inoculated with the 
test organism. Zones of inhibition around the cefoxitin disc were 
observed after overnight incubation. Isolates that yielded a zone 
diameter less than 18 mm were labeled as AmpC β-lactamases 
positive. All the strains were screened for the AmpC β-lactamase 
production by the disc antagonism test (DAT) [7]and boronic acid 
disk potentiation test (BADPT) [9]. 
MBL 
The metallo-β-lactamase production was detected by three tests: 
double disk synergy tests (DDST) [10], combined disk test (CDT) [7] 
and modified Hodge test (MHT) [10]. 
PCR amplification of class A and class B β-lactamase genes 
Multiplex PCR assay was performed to detect and differentiate three 
MBL encoding genes blaVIM-2, blaIMP-1 and blaSIM-1 families in a 
single reaction [11]. PCR for ESBL encoding genes blaPER-1 and 
blaCTX-M 1, 2, 9 was performed as described earlier [12]. 
Statistical methods 
Data was analyzed using STATA version 11.1 (Stata Inc, College 
Station, TX, USA). To compare categorical variables, Fisher’s exact 
test was used. Sensitivity, specificity, positive and negative 
predictive values (PPV and NPV), for phenotypic test and PCR 
against gold standard.  
RESULTS  
Isolates 
During the study, a total of 270 samples was received from which 80 
were confirmed as P. aeruginosa isolates obtained from the patients 
of LRTI. 
Antimicrobial susceptibilities of clinical strains 
Maximum sensitivity (90%) was seen with imipenem, followed by 
amikacin (86.2%) meropenem (72.5%) and piperacillin/tazobactam 
(71.2%). 
The comparative antimicrobial resistances of β-lactamase producers 
and non-β-lactamase producers are summarized in (table 1). 
 
Table 1: Comparison of the antimicrobial resistance (%) between the class A and/or class B β-lactamase producer and β-lactamase non 
producer P. aeruginosa isolates 
Antimicrobial agent β-lactamase producer (n=22) Non β-lactamase producer (n=58) P-Value  
AMK 33.3 66.7 NS 
ATM 40.0 60.0 0.012* 
CIP 41.1 58.9 0.019* 
CAZ 40.0 60.0 0.001* 
FEP 39.6 60.4 0.009* 
CRO 35.1 64.9 0.027* 
IMP 25.0 75.0 NS 
TZP 52.6 47.3 0.005* 
TOB 47.8 52.1 0.010* 
MEM 47.5 52.5 0.000* 
A/C 29.3 70.7 NS 
GEN 29.0 71.0 NS 
AMP 28.2 78.8 NS 
LVX 36.0 64.0 0.002* 
*P≤0.05 is considered as being significant, *NS: Not significant 
Abbreviations: AMK-amikacin, ATM-aztreonam,CIP-ciprofloxacin,CAZ-ceftazidime, FEP-cefepime,CRO-ceftriaxon,IPM-imipenem,TZP-piperacillin–
tazobactam,TOB-tobramycin, FOX-cefoxitin, GEN-gentamicin, AMP-ampicillin, A/C-amoxicillin+clavulanic acid, LVX-levofloxacin. 
 
MIC 
The highest MIC for meropenem was 16µg/ml for 17 isolates. The 
highest MIC observed for ceftazidime was 128µg/ml for 12 P. 
aeruginosa isolates. 
MDR 
Among 80 (52) P. aeruginosa isolates were found to be MDR. 
Multidrug resistance was more prevalent in meropenem-resistant 
isolates than meropenem-susceptible isolates (92.5% vs 32.4%).  
Screening for MBL  
Out of 40 meropenem resistant isolates, 34 were MBL producers of 
which 22 (55%) were found to be positive in DDST and 12 (30%) in 
the CDT and none were positive in the MHT.  
Screening for ESBL 
Similarly, of 50 ceftazidime resistant isolates, 23 were ESBL 
producing; CDM gave a positive result in 13 (26%) isolates, whereas 
DDAT detected in 10 (20%) isolates.  
Screening for AmpC  
All P. aeruginosa isolates were tested for AmpC-β-lactamase 
production. Cefoxitin resistance was evident in 30 isolates, while 21 
isolates were confirmed to be AmpC β-lactamase producers. Among 
the test isolates, 12 (40%) were detected by DAT as AmpC 
producers while 9 (30%) were confirmed by BADPT.  
Genotype detection of β-lactamases genes 
MBL genes 
Multiplex PCR showed the presence of MBL genes in 59% (20/34) 
isolates; most common MBL subtype was blaVIM-2 (11/34; 32.3%) five 
isolates (14.7%) were positive for blaIMP-1 gene and only four (12%) 
were positive for blaSIM-1. Four isolates carried all three MBL genes.  
ESBL genes 
Genes encoding ESBLs were detected in 70% (16/23) of the isolates. 
CTXM-2 was detected in seven (30.4%) and PER-1gene was also 
detected in seven 
CDM had the highest sensitivity (92%) and specificity (97%) for 
detection of ESBL as compared to DDAT (table-3). 
isolates (30.4%) where as, two (8.6%) isolates 
carried CTXM-1. None of the MDR P. aeruginosa carried CTXM-9 
genes in our study.  
None of the screening method showed a complete correlation when 
compared to PCR. The CDT had the highest sensitivity (92%) and 
specificity (99%) for detection of MBL (table 2). 
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Table 2: Comparison of MBL phenotypic test against PCR 
Phenotypic method 
 
No. of PCR-confirmed 
MBL-carrying 
Organisms (n =12) 
No. of PCR-confirmed non 
MBL-carrying 









CDT 11(92%) 1(1.4%) 92 99 92 99 
DDST  11(92%)  11(16.1%)  92  84  50  98.2 
 
Table 3: Comparison of ESBL phenotypic test against PCR 
Phenotypic method 
 
No. of PCR-confirmed 
ESBL-carrying 
Organisms (n =12) 
No. of PCR-confirmed 
Non ESBL-carrying 









CDM 11 (92%) 2(3%) 92 97 85 99 
DDAT 12(100%) 2(3%) 83.3 100 100 97.1 
 
DISCUSSION 
P. aeruginosa has emerged as the most common dreadful gram 
negative bacilli found in various health care associated infections all 
over the world due to its virulence and ability to resist killing by 
various antibiotics. The bacterial resistance is on the rise, creating 
clinical as well as economical issues [13].  
In India, the prevalence rate of P. aeruginosa infection varies from 
10.5% to 30% [14]. Our study corroborated the same with a 
prevalence rate of 29.6%. 
The Percentage of MDR P. aeruginosa in India ranges from 11.36% 
reported by Idris et al.,[15], 91.6% reported by Panranjothi et al., 
[16],Our study showed 65% P. aeruginosa were as MDR, consistent 
with previous data. 
Among the 3rd
Out of 80 P. aeruginosa isolates, 22 were β-lactamase producers and 
58 non β-lactamase producers. The β-lactamase producers were 
significantly resistant to piperacillin+tazobactam than non-
producers (*P<0.005). 
 cephalosporins drugs, ceftazidime (62.5%) and 
ceftriaxone (67.5%), showed the highest resistance. The similar 
finding was reported by Diwivedi et al.,(63%) [17] and Senthamarai 
et al., (65.38%) [13]. 
Our study showed that among the 80 P. aeruginosa isolates, only 
46.0% P. aeuginosa isolates were ESBL producers, which was 
comparable to previous studies [18-21]. 
In P. aeruginosa production of ESBL is usually less because, because 
their resistance is mediated by various other mechanisms such as 
the production of MBL, porins mutation and the loss of certain outer 
membrane proteins and efflux pumps.  
Out of 23 ESBL producers, 16 carried β-lactamase producing genes. 
bla PER-1 carried 30.4% and blaCTX-M-2 carried 30.4 %, followed 
by blaCTX-M-1 carried 8.6 %. Surprisingly, none of our isolates were 
positive for blaCTX-M-9 genes.  
An earlier reported 87% prevalence of blaCTX-M enzyme amongst 
ESBL producers [22]. However, our study reported only 69.5% 
prevalence of ESBL genes. 
The emergence of MBL mediated resistance in India is of serious 
concern. Carbapenems are effective therapeutic agents against 
highly resistant pathogen such as P. aeruginosa. In our study, the 
frequency of the MBL producing P. aeruginosa was 26.2%. Another 
recent study by Varaiya et al.,showed 20.8% of MDR P. aeruginosa 
were to be MBL producers [23] whereas, Upadhyay et al., Reportedly 
46.6% of MBL production among MDR P. aeruginosa isolates [7]. 
In our experience, out of the 40 meropenem resistant isolates, all the 
34 were found to be positive for MBL by three different tests to 
detect MBL producers, in which MHT was unable to detect none. 
CLSI [5] recommends MHT for detection of carbapenemases activity 
in Enterobacteriaceae only. DDST detected 55% isolates to be MBL 
producers as opposed to 30% confirmed by CDT.  
In total, 59% of MBL producers carried either blaIMP-1, blaVIM-2 
and blaSIM-1 gene. The presence of blaVIM-2 gene appears to be 
more prevalent in our setup, wherein P. aeruginosa isolates were 
positive for the blaVIM-2 gene. Fortunately, in our setup we 
encountered very less prevalence of resistance genes among P. 
aeruginosa when compared to other studies. Amp-C production was 
quite high in our isolates compared to other studies. [7] 
When compared statistical, results showed that the CDT had an 
excellent sensitivity and a specificity (sensitivity>92%, 
specificity>99%), then DDST. In comparison, ESBL results showed 
that the CDM had a sensitivity and specificity (sensitivity>92%, 
specificity>97%). Whereas, the DDAT had a sensitivity of 83.3% and 
specificity of 100%. Overall, the combined-disk test for MBL and 
CDM for ESBL better for detection. It is easy to perform, and the 
materials used are low-priced, safe, and easily available, making it 
highly applicable in routine clinical laboratories. 
Our study validates a simple and highly sensitive phenotypes 
method for the detection of MBL and ESBL production in P. 
aeruginosa isolated from LRTI patients. Higher frequency of MDR P. 
aeruginosa along with production of beta lactamases enzyme is a 
worrying sign for the clinicians and microbiologists. We recommend 
the routine surveillance of antibiotic resistance in the hospital. 
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